DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Stock Information for Aptorum Group Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aptorum Group Limited

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test
Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Andean Precious Metals Receives Final Approval for Uplisting to Toronto Stock Exchange

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.